Abstract
BackgroundThe aim of the study is to evaluate the role and efficacy of transvaginal ultrasound in detection of endometrial changes in breast cancer patients under hormonal therapy in correlation with histopathological results of endometrial biopsies. Fifty patients with breast cancer under tamoxifen were subjected to transvaginal ultrasonography, and the results are compared with histopathological results of endometrial biopsies from March 2018 to November 2018.ResultsTwenty-two patients (44%) had normal regular endometrium, and twenty-eight patients (56%) had abnormal ultrasonographic appearance with different types of pathology; there were 24 patients (85.7%) with endometrial abnormality and 4 patients (14.3%) with adnexal pathology. The twenty-four patients with endometrial abnormality were as follows: 10% endometrial atrophy, 4% endometrial carcinoma, 14% endometrial hyperplasia, and 7% endometrial polyp with sensitivity of 92.9% and accuracy of 96% in comparison to histopathology results.ConclusionWe found in our study that transvaginal ultrasonography is a sensitive and rather specific method to evaluate the endometrial lesions, so we concluded that it is a necessary screening tool for detection of endometrial abnormalities in breast cancer patients under hormonal therapy.
Highlights
The aim of the study is to evaluate the role and efficacy of transvaginal ultrasound in detection of endometrial changes in breast cancer patients under hormonal therapy in correlation with histopathological results of endometrial biopsies
Prospective study was carried out on 50 patients known with breast carcinoma who came to the radiology department at Helwan University; their age ranged from 32 to 55 years old; their mean age was 44.90 years and standard deviation ± 5.80 years
All of the patients were examined by transvaginal ultrasonography (TVUS) as a routine follow-up; 9 patients (18%) were complaining from abnormal vaginal bleeding with various degrees
Summary
The aim of the study is to evaluate the role and efficacy of transvaginal ultrasound in detection of endometrial changes in breast cancer patients under hormonal therapy in correlation with histopathological results of endometrial biopsies. Fifty patients with breast cancer under tamoxifen were subjected to transvaginal ultrasonography, and the results are compared with histopathological results of endometrial biopsies from March 2018 to November 2018. Postoperative adjuvant systemic therapy prolongs survival in selected women with breast cancer and reduces the odds of death by 25% per year [1]. Since the early 1980s, tamoxifen has become the standard adjuvant therapy for patients with breast cancer, reducing the risk for a second case of contralateral primary breast cancer from 30 to 50% [2]. Several reports have cited an increased incidence of endometrial abnormality, ranging from polyps to cancer, in women receiving tamoxifen [2]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
